Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 6/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583398 | 1.00 | MMP8 (0.53) | MMP8FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL25381978 | 0.82 | MMP8 (0.50) | MMP8ERAP2ERAP1LNPEP | |
| SCHEMBL10685757 | 0.80 | ECE1 (0.58) | MMP8ERAP2ERAP1LNPEPMME | |
| SCHEMBL1200181 | 0.79 | RNPEP (0.57) | RNPEPMMESLC7A5ALDH1A1 | |
| SCHEMBL28937194 | 0.75 | FOLH1 (0.54) | MMP8FOLH1MME | |
| SCHEMBL27363047 | 0.74 | FOLH1 (0.48) | FOLH1SLC7A5 | |
| Hydroxyamine SCHEMBL20817080 | 0.74 | SLC7A5 (0.59) | RNPEPMMESLC7A5ALDH1A1 | |
| SCHEMBL180035 | 0.72 | RNPEP (0.50) | RNPEPMMESLC7A5ALDH1A1 | |
| SCHEMBL5143583 | 0.71 | RNPEP (0.44) | FOLH1RNPEPMMESLC7A5ALDH1A1 | |
| SCHEMBL8159103 | 0.71 | MME (0.62) | FOLH1RNPEPMMESLC7A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501798-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501798-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501798-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227497-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227497-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227497-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110251249-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251249-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989484-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989484-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989484-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2297113-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009134741-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134741-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MMP8 2395/4885FOLH1 1857/4885ERAP2 281/4885 |
| US-20110251249-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MMP8 2395/4885FOLH1 1857/4885ERAP2 281/4885 |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MMP8 2395/4885FOLH1 1857/4885ERAP2 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.